FGF21 and obesity due to melanocortin 4 receptor deficiency: Pharmacologically, recombinant FGF21 as a therapeutic intervention was reported to reduce obesity, as well as adiposity, hyperglycemia, and hyperinsulinemia, in both rodents and nonhuman primates [9, 10].